The diagnosis of cystic fibrosis.
暂无分享,去创建一个
[1] T. Boat,et al. OBSTRUCTIVE AZOOSPERMIA AS A DIAGNOSTIC CRITERION FOR THE CYSTIC FIBROSIS SYNDROME , 1982, The Lancet.
[2] P. Hu,et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. , 1995, The New England journal of medicine.
[3] David Handelsman,et al. Young's syndrome. Obstructive azoospermia and chronic sinopulmonary infections. , 1984, The New England journal of medicine.
[4] Q. Al-Awqati,et al. Defective acidification of the biosynthetic pathway in cystic fibrosis , 1993, Journal of Cell Science.
[5] P. di Sant'Agnese,et al. Low sweat electrolytes in a patient with cystic fibrosis. , 1980, The American journal of medicine.
[6] D. Riches,et al. Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.
[7] M. Knowles,et al. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. , 1995, Human gene therapy.
[8] G. Loughlin,et al. Clinical application of transepithelial potential difference measurements in cystic fibrosis. , 1987, The Journal of pediatrics.
[9] M. Knowles,et al. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. , 1981, The New England journal of medicine.
[10] R. Stern,et al. Treatment and Prognosis of Symptomatic Gallbladder Disease in Patients with Cystic Fibrosis , 1986, Journal of pediatric gastroenterology and nutrition.
[11] H. Joos,et al. PARANASAL SINUSES IN CYSTIC FIBROSIS. INCIDENCE OF ROENTGEN ABNORMALITIES. , 1964, American journal of diseases of children.
[12] J. Carlin,et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis , 1996, Pediatric pulmonology.
[13] F. Accurso,et al. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. , 1991, The Journal of pediatrics.
[14] M. Welsh,et al. Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. , 1995, EMBO Journal.
[15] C. Arvanitakis,et al. Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid. , 1978, The Journal of pediatrics.
[16] D. Geddes,et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. , 1993, The European respiratory journal.
[17] M. Drumm,et al. 3849+10 kb C→T mutation and disease severity in cystic fibrosis , 1995, The Lancet.
[18] P. Lankisch. Exocrine pancreatic function tests. , 1982, Gut.
[19] H. Shwachman,et al. Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes. , 1975, Pediatrics.
[20] P. Phelan,et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis , 1995, BMJ.
[21] J C Olsen,et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.
[22] J. Zieleński,et al. Cystic fibrosis: genotypic and phenotypic variations. , 1995, Annual review of genetics.
[23] R. Gibson,et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. , 1991, The American review of respiratory disease.
[24] M. Knowles,et al. Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. , 1996, American journal of respiratory and critical care medicine.
[25] C. Hunt,et al. Increased sweat chloride levels associated with prostaglandin E1 infusion. , 1985, The Journal of pediatrics.
[26] M. King,et al. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. , 1990, The American review of respiratory disease.
[27] M. King,et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. , 1990, The New England journal of medicine.
[28] M. Konstan,et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. , 1994, American journal of respiratory and critical care medicine.
[29] L. Tsui,et al. Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.
[30] L. Cantley,et al. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. , 1986, The Journal of clinical investigation.
[31] M Claustres,et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. , 1995, The New England journal of medicine.
[32] G. Barbero,et al. Stool trypsin and chymotrypsin. Value in the diagnosis of pancreatic insufficiency in cystic fibrosis. , 1966, American journal of diseases of children.